Remission Up for Mepolizumab in Eosinophilic Granulomatosis

Share this content:
Remission Up for Mepolizumab in Eosinophilic Granulomatosis
Remission Up for Mepolizumab in Eosinophilic Granulomatosis

THURSDAY, May 25, 2017 (HealthDay News) -- Mepolizumab is associated with significantly more weeks in remission than placebo among patients with eosinophilic granulomatosis with polyangiitis, according to a study published in the May 18 issue of the New England Journal of Medicine.

Michael E. Wechsler, M.D., from National Jewish Health in Denver, and colleagues conducted a multicenter phase 3 trial involving participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis. In addition to standard care, participants were randomized to receive mepolizumab (68 patients) or placebo (68 patients) administered every four weeks for 52 weeks.

The researchers found that, compared with placebo, mepolizumab treatment correlated with significantly more accrued weeks of remission (28 versus 3 percent of participants had ≥24 weeks of accrued remission, respectively; odds ratio, 5.91) and a higher percentage of participants in remission at weeks 36 and 48 (32 versus 3 percent; odds ratio, 16.74). Remission did not occur in 47 and 81 percent of participants in the mepolizumab and placebo groups, respectively. The annualized relapse rate was 1.14 and 2.27 in the mepolizumab and placebo groups, respectively (rate ratio, 0.50). Overall, 44 and 7 percent of those taking mepolizumab and placebo had an average daily dose of prednisolone or prednisone of 4.0 mg or less per day during weeks 48 through 52 (odds ratio, 0.20).

"The results of our trial show an advance for patients with this rare disease," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including GlaxoSmithKline, which manufactures mepolizumab and funded the study.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

CDC Launches Campaign to Fight Prescription Opioid Epidemic

CDC Launches Campaign to Fight Prescription Opioid Epidemic

Rx Awareness campaign uses testimonials to educate the public, increase awareness about risks

Liraglutide Linked to Reduction in VAT, Improvement in -Index

Liraglutide Linked to Reduction in VAT, Improvement in ...

Significant improvement in IGF-II serum levels with liraglutide for obese with prediabetes, early T2DM

Nut Consumption Linked to Nutritionally Rich Food Intake

Nut Consumption Linked to Nutritionally Rich Food Intake

Nut consumers eat more fruits, vegetables, less red meat, and have lower BMI than non-nut consumers

is free, fast, and customized just for you!

Already a member?

Sign In Now »